ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications

Permanent link
https://hdl.handle.net/10037/13324
DOI
https://doi.org/10.1016/j.blre.2017.05.001
Thumbnail
View/Open
article.pdf (804.3Kb)
Publisher's version (PDF)
Date
2017-05-03
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Arranz, Lorena; Arriero Sanchez, Maria Del Mar; Villatoro, Alicia
Abstract
Interleukin-1β (IL-1β) is a pleiotropic cytokine that exerts multiple roles in both physiological and pathological conditions. It is produced by different cell subsets, and drives a wide range of inflammatory responses in numerous target cells. Enhanced IL-1β signaling is a common event in patients of hematological malignancies. Recent body of evidence obtained in preclinical models shows the pathogenic role of these alterations, and the promising therapeutic value of IL-1 targeting. In this review, we further highlight a potential contribution of IL-1β linking to complications and autoimmune disease that should be investigated in future studies. Hence, drugs that target IL-1 may be helpful to improve outcome or reduce morbidity in patients. Some of them are FDA-approved, and used efficiently against autoimmune diseases, like IL-1 receptor antagonist. In the clinic, however, this agent seems to have limited properties. Current improved drugs will allow to determine the true potential of IL-1 and IL-1β targeting as therapy in hematological malignancies and their related complications.
Is part of
Villatoro, A. (2022). The role of interleukin-1 receptor antagonist in normal and malignant hematopoiesis. (Doctoral thesis). https://hdl.handle.net/10037/26329
Publisher
Springer Verlag (Germany)
Citation
Arranz, L., Arriero Sanchez, M.D.M. & Villatoro, A.E. (2017). Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications. Blood reviews, 31(5), 306-317. https://doi.org/10.1016/j.blre.2017.05.001
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (medisinsk biologi) [1103]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)